FDA approved pembrolizumab for 3rd-line PMBCL in adult and pediatric patients

/1 Comment/in , , , /by

 

  • On June 13, 2018, the US FDA has granted accelerated approval to pembrolizumab (KeytrudaⓇ, Merck & Co. Inc.) for the treatment of adult and pediatric patients with primary mediastinal large B-cell lymphoma (PMBCL), relapsed after two or more prior lines of prior therapy.
You might also like
Pembrolizumab FDA approved for adjuvant treatment of melanoma
Lorlatinib FDA approved for metastatic ALK-positive NSCLC
Brentuximab vedotin (Adcetris®) plus chemotherapy approved for several CD30 expressing lymphomas
Olaparib (Lynparza) FDA approved as maintenance for BRCAm ovarian cancer
Discontinuation, post-discontinuation monitoring criteria, and guidance for treatment re-initiation in patients taking nilotinib for Ph+ CML with a sustained molecular response
Emapalumab FDA approved in adult and paediatric patients with primary hemophagocytic lymphohistiocytosis
FDA approved abiraterone acetate tablets plus prednisone for metastatic high-risk CSPC
Making sense of 1st-line immunotherapy in non-small cell lung cancer (NSCLC)
1 reply

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *

FDA approved pembrolizumab for chemotherapy-refractory r/m cervical cancer with...Bevacizumab in combination with carboplatin and paclitaxel FDA approved for...